Avidity Partners Management LP
- SEC CIK
- 0001791827
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 63
- +2 vs. Q4 2024
- Portfolio value
- $484.9M
- −$518.3M (−51.7%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| BSXBoston Scientific Corp | Stock | 336,000 | $33.9M | 7.0% | −179,000−34.8% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,720,902 | $31.2M | 6.4% | −1,152,098−40.1% | Reduced | History |
| UNHUnitedHealth Group Inc | Stock | 50,500 | $26.4M | 5.5% | −9,500−15.8% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 980,942 | $24.0M | 5.0% | −116,858−10.6% | Reduced | History |
| HUMHumana Inc | Stock | 81,000 | $21.4M | 4.4% | −8,200−9.2% | Reduced | History |
| NTRANatera, Inc. | COM | 119,200 | $16.9M | 3.5% | −104,600−46.7% | Reduced | History |
| REGNRegeneron Pharmaceuticals, Inc. | COM | 25,400 | $16.1M | 3.3% | +17,000+202.4% | Added | History |
| EXASExact Sciences Corp | COM | 353,000 | $15.3M | 3.2% | −250,011−41.5% | Reduced | History |
| BEAMBeam Therapeutics Inc. | COM | 709,517 | $13.9M | 2.9% | +709,517 | New | History |
| GKOSGLAUKOS Corp | COM | 134,000 | $13.2M | 2.7% | −36,000−21.2% | Reduced | History |
| DXCMDexcom Inc | COM | 180,000 | $12.3M | 2.5% | −138,000−43.4% | Reduced | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 322,100 | $11.7M | 2.4% | −29,900−8.5% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 925,000 | $11.4M | 2.3% | −575,000−38.3% | Reduced | History |
| CORCencora, Inc. | Stock | 39,300 | $10.9M | 2.3% | +39,300 | New | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 80,000 | $9.93M | 2.0% | −154,500−65.9% | Reduced | History |
| THCTenet Healthcare Corp | COM NEW | 72,000 | $9.68M | 2.0% | −65,000−47.4% | Reduced | History |
| NBIXNeurocrine Biosciences Inc | Stock | 85,700 | $9.48M | 2.0% | −134,700−61.1% | Reduced | History |
| DHRDanaher Corp | Stock | 44,500 | $9.12M | 1.9% | −22,500−33.6% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 77,000 | $8.98M | 1.9% | −111,000−59.0% | Reduced | History |
| INSMINSMED Inc | COM PAR $.01 | 107,000 | $8.16M | 1.7% | −125,800−54.0% | Reduced | History |
| OGNOrganon & Co. | Stock | 535,000 | $7.97M | 1.6% | +535,000 | New | History |
| TMOThermo Fisher Scientific Inc. | Stock | 15,500 | $7.71M | 1.6% | −29,100−65.2% | Reduced | History |
| XENEXenon Pharmaceuticals Inc. | COM | 229,000 | $7.68M | 1.6% | −245,000−51.7% | Reduced | History |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | 94,000 | $7.62M | 1.6% | +94,000 | New | – |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 529,000 | $7.61M | 1.6% | −636,800−54.6% | Reduced | History |
| RVMDRevolution Medicines, Inc. | COM | 213,000 | $7.53M | 1.6% | −233,200−52.3% | Reduced | History |
| TEVATeva Pharmaceutical Industries Ltd | SPONSORED ADS | 481,000 | $7.39M | 1.5% | +481,000 | New | History |
| AVTRAvantor, Inc. | COM | 453,000 | $7.34M | 1.5% | −494,000−52.2% | Reduced | History |
| IDYAIDEAYA Biosciences, Inc. | COM | 445,000 | $7.29M | 1.5% | −681,700−60.5% | Reduced | History |
| DOCSDoximity, Inc. | CL A | 122,500 | $7.11M | 1.5% | +122,500 | New | History |
| JANXJanux Therapeutics, Inc. | COM | 258,000 | $6.97M | 1.4% | −483,900−65.2% | Reduced | History |
| HQYHealthequity, Inc. | COM | 78,000 | $6.89M | 1.4% | +78,000 | New | History |
| BPMCBlueprint Medicines Corp | COM | 68,500 | $6.06M | 1.3% | −108,100−61.2% | Reduced | History |
| UTHRUnited Therapeutics Corp | COM | 16,800 | $5.18M | 1.1% | +16,800 | New | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 800,000 | $5.02M | 1.0% | −590,100−42.5% | Reduced | History |
| IMUXImmunic, Inc. | COM | 4,454,408 | $4.86M | 1.0% | −3,511,992−44.1% | Reduced | History |
| BRKRBruker Corp | COM | 115,000 | $4.80M | 1.0% | +38,700+50.7% | Added | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 2,197,270 | $4.68M | 1.0% | −497,330−18.5% | Reduced | History |
| CNTXContext Therapeutics Inc. | COM | 7,477,200 | $4.58M | 0.9% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 352,124 | $3.61M | 0.7% | 00.0% | Unchanged | History |
| QUREuniQure N.V. | SHS | 336,200 | $3.56M | 0.7% | +114,200+51.4% | Added | History |
| BHVNBiohaven Ltd. | COM | 145,000 | $3.49M | 0.7% | −77,900−34.9% | Reduced | History |
| ARVNArvinas, Inc. | COM | 413,162 | $2.90M | 0.6% | −944,838−69.6% | Reduced | History |
| ACADAcadia Pharmaceuticals Inc | COM | 169,000 | $2.81M | 0.6% | +169,000 | New | History |
| RPRXRoyalty Pharma plc | SHS CLASS A | 87,000 | $2.71M | 0.6% | +87,000 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 75,000 | $2.59M | 0.5% | +75,000 | New | History |
| KZRKezar Life Sciences, Inc. | COM | 502,600 | $2.45M | 0.5% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 57,000 | $2.31M | 0.5% | −25,000−30.5% | Reduced | History |
| SLNOSoleno Therapeutics Inc | COM | 32,000 | $2.29M | 0.5% | +32,000 | New | History |
| CAPRCapricor Therapeutics, Inc. | COM NEW | 239,000 | $2.27M | 0.5% | +239,000 | New | History |
| LXEOLexeo Therapeutics, Inc. | COM | 645,000 | $2.24M | 0.5% | +645,000 | New | History |
| VERAVera Therapeutics, Inc. | CL A | 91,000 | $2.19M | 0.5% | −9,000−9.0% | Reduced | History |
| RGNXREGENXBIO Inc. | COM | 260,000 | $1.86M | 0.4% | −272,000−51.1% | Reduced | History |
| IONSIonis Pharmaceuticals Inc | COM | 60,000 | $1.81M | 0.4% | +60,000 | New | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 40,000 | $1.80M | 0.4% | −626,200−94.0% | Reduced | History |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 68,000 | $1.39M | 0.3% | −286,000−80.8% | Reduced | History |
| AGLagilon health, inc. | COM | 305,100 | $1.32M | 0.3% | +305,100 | New | History |
| SCYXScynexis Inc | COM NEW | 1,228,910 | $1.17M | 0.2% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 23,000 | $868.5K | 0.2% | +23,000 | New | History |
| KPTIKaryopharm Therapeutics Inc. | COM NEW | 134,566 | $503.3K | 0.1% | 00.0% | UnchangedConverted for a 1-for-15 split | History |
| ELVNEnliven Therapeutics, Inc. | COM | 11,300 | $222.4K | <0.1% | +11,300 | New | History |
| HYPRHyperfine, Inc. | COM CL A | 222,174 | $159.1K | <0.1% | −966,004−81.3% | Reduced | History |
| RVPHReviva Pharmaceuticals Holdings, Inc. | COM | 138,000 | $131.6K | <0.1% | +138,000 | New | History |
Options (4)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q4 2024 (17)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| ISRGIntuitive Surgical Inc | COM NEW | 64,800 | $33.8M | 3.4% | History |
| ACHCAcadia Healthcare Company, Inc. | COM | 658,000 | $26.1M | 2.6% | History |
| KYMRKymera Therapeutics, Inc. | COM | 500,000 | $20.1M | 2.0% | History |
| ILMNIllumina, Inc. | COM | 109,700 | $14.7M | 1.5% | History |
| ABBVAbbVie Inc. | Stock | 80,700 | $14.3M | 1.4% | History |
| RCKTRocket Pharmaceuticals, Inc. | COM | 1,053,300 | $13.2M | 1.3% | History |
| BMYBristol Myers Squibb Co | Stock | 215,000 | $12.2M | 1.2% | History |
| TMDXTransMedics Group, Inc. | COM | 192,400 | $12.0M | 1.2% | History |
| SGRYSurgery Partners, Inc. | Stock | 514,200 | $10.9M | 1.1% | History |
| ORICOric Pharmaceuticals, Inc. | COM | 1,265,200 | $10.2M | 1.0% | History |
| INCYIncyte Corp | COM | 129,600 | $8.95M | 0.9% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 62,000 | $8.54M | 0.9% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 97,000 | $8.10M | 0.8% | History |
| KROSKeros Therapeutics, Inc. | COM | 210,000 | $3.32M | 0.3% | History |
| DYNDyne Therapeutics, Inc. | COM | 96,000 | $2.26M | 0.2% | History |
| COGTCogent Biosciences, Inc. | COM | 287,104 | $2.24M | 0.2% | History |
| BLUEbluebird bio, Inc. | COM NEW | 81,555 | $680.2K | 0.1% | History |